Results For "Selective-JAK-inhibitors"

1 News Found

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

News | May 13, 2026

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments

Latest Stories

Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis

Breakthrough wearable heart failure therapy enables earlier hospital discharge: UK trial

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

Dushyant Sapre Founder and CEO, SwishX

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Duraisamy Rajan Palani Founder and CEO, Archimedis Digital

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Patient-centric innovation driving fight against neglected diseases: Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Sanjay Sarin, Continental Lead Asia and South Asia Director, DNDi

Packaging